Czy wynik CHA2DS2-VASc determinuje leczenie przeciwzakrzepowe u pacjentów z migotaniem przedsionków? Dane z  POLish Atrial Fibrillation (POL-AF) Registry?

Szpotowicz, Anna; Gorczyca, Iwona; Uziębło‐Życzkowska, Beata; Maciorowska, Małgorzata; Wójcik, Maciej; Błaszczyk, Robert; Kapłon‐Cieślicka, Agnieszka; Gawałko, Monika; Budnik, Monika; Tokarek, Tomasz; Rajtar-Salwa, Renata; Bil, Jacek; Wojewódzki, Michał; Bednarski, Janusz; Bakuła-Ostalska, Elwira; Tomaszuk‐Kazberuk, Anna; Szyszkowska, Anna; Wełnicki, Marcin; Mamcarz, Artur; Krzciuk, Małgorzata; Wożakowska−Kapłon, Beata

doi:10.5603/fc.a2021.0053

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not observe differences in a thromboembolic risk assessed based on CHADS 2 and CHA 2 DS 2 -VASc between OAC-treated and untreated groups. Similarly, Szpotowicz et al [ 21 ] found that the CHA 2 DS 2 -VASc score did not predict OAC use in the studied cohort of patients with AF.…”

Section: Discussionmentioning

confidence: 78%

Anticoagulant Treatment in Patients with AF and Very High Thromboembolic Risk in the Era before and after the Introduction of NOAC: Observation at a Polish Reference Centre

Bielecka

Gorczyca

Ciba-Stemplewska

et al. 2023

IJERPH

Self Cite

View full text Add to dashboard Cite

Atrial fibrillation (AF) is associated with an increased risk of stroke. Therefore, patients with AF require appropriate management and anticoagulant therapy. To balance therapy risks and benefits, oral anticoagulants (OAC) treatment should be ‘tailored’ in patients at a high risk of stroke and bleeding. However, some studies have demonstrated that certain groups of patients do not receive anticoagulants despite the high risk of stroke or thromboembolism. The study aimed to analyse therapeutic methods of stroke prevention in very high-risk patients (CHA2DS2-VASc score of ≥5 in men and ≥6 in women), identify factors predisposing against the use of OACs and assess the administration of anticoagulants before the introduction of non-vitamin K antagonist OAC (NOAC) in 2004–2011 and beyond (years 2012–2019). The analysis covered 2441 patients with AF at a very high thromboembolic risk who were hospitalised in a reference cardiological centre from 2004 to 2019. Data concerning patients’ sex, age, comorbidities, type of AF, renal and echocardiographic parameters, reasons for hospitalisation and applied treatment were collected from medical records. HAS-BLED, CHADS2, and CHA2DS2-VASc scores were calculated for all patients. The treatment with oral anticoagulants was compared in the entire population over 2004–2011 and 2012–2019. In this study, a fifth of patients were not treated with OAC. Most patients hospitalised in the years 2012–2019 were treated with OAC. The predictors of not using OAC turned out to be: age of >74 years, heart failure, cancer, paroxysmal AF, and acute coronary syndrome (ACS) or elective coronary angiography/percutaneous coronary intervention (PCI) as a reason for hospitalisation. The introduction of NOAC was associated with a decline in the use of VKA (from 62% to 19.1%) and APT (from 29.1% to 1.3%). This study outlines reasons to initiate OAC treatment in very high-risk patients in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 78%